Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Cash: 2011-2024

Historic Change in Cash for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $185.0 million.

  • Ptc Therapeutics' Change in Cash fell 169.33% to -$346.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.5 million, marking a year-over-year decrease of 59.12%. This contributed to the annual value of $185.0 million for FY2024, which is 41.14% down from last year.
  • Ptc Therapeutics' Change in Cash amounted to $185.0 million in FY2024, which was down 41.14% from $314.4 million recorded in FY2023.
  • Ptc Therapeutics' Change in Cash's 5-year high stood at $314.4 million during FY2023, with a 5-year trough of -$79.2 million in FY2020.
  • Over the past 3 years, Ptc Therapeutics' median Change in Cash value was $185.0 million (recorded in 2024), while the average stood at $199.4 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Change in Cash tumbled by 162.85% in 2020, and later spiked by 616.95% in 2022.
  • Ptc Therapeutics' Change in Cash (Yearly) stood at -$79.2 million in 2020, then spiked by 75.90% to -$19.1 million in 2021, then soared by 616.95% to $98.7 million in 2022, then soared by 218.48% to $314.4 million in 2023, then slumped by 41.14% to $185.0 million in 2024.